|
|
Post by jkendra on Feb 27, 2024 16:07:20 GMT -5
Afrezza with a nice $2M+ jump from previous quarter.
|
|
|
|
Post by alethea on Feb 27, 2024 16:46:14 GMT -5
MannKind Corporation reports impressive financial results for Q4 2023 and full year 2023 with total revenues of $199M, net income of $1M, and cash position of $302M. Positive revenue growth driven by Afrezza and collaborations. Clinical trials progressing well with upcoming data read-outs and FDA submissions. WoW And Q4 Actual Earnings Of 58M vs Estimated 53M is a very nice beat. Might even say sort of a kickas$ beat. Really nice quarter. |
|
